Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development

Reck, 2014, Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 25, iii27, 10.1093/annonc/mdu199

Masters, 2015, Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline update, J Clin Oncol, 33, 3488, 10.1200/JCO.2015.62.1342

Yu, 2013, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers, Clin Cancer Res, 19, 2240, 10.1158/1078-0432.CCR-12-2246

Jänne, 2015, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, N Engl J Med, 372, 1689, 10.1056/NEJMoa1411817

Ward, 2013, Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR), J Med Chem, 56, 7025, 10.1021/jm400822z

Finlay, 2014, Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor, J Med Chem, 57, 8249, 10.1021/jm500973a

Cross, 2014, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer, Cancer Discov, 4, 1046, 10.1158/2159-8290.CD-14-0337

Ballard, 2013, Mol Cancer Ther, 12, B212, 10.1158/1535-7163.TARG-13-B212

P Ballard, P Yang, D Cross et al. Preclinical activity of AZD9291 in EGFR-mutant NSCLC brain metastases. In Abstract at WCLC 2015, Denver, CO, USA, 6–9 September 2015.